Counterpoint: Vancomycin and Staphylococcus aureus--An Antibiotic Enters Obsolescence
Division of Infectious Disease and Geographic Medicine, Department of Medicine, Stanford University, CA, USA. Clinical Infectious Diseases
(Impact Factor: 8.89).
07/2007; 44(12):1543-8. DOI: 10.1086/518452
The efficacy of vancomycin for the treatment of patients with infections due to Staphylococcus aureus is impaired by its poor tissue penetration and by its relatively weak antibacterial activity--an activity that is declining as S. aureus evolves. Neither dose escalation nor use of vancomycin in combination with other antibiotics that have antistaphylcoccal activity has been demonstrated to safely enhance its therapeutic efficacy. Although no clinical trials suggest superiority of vancomycin over any comparator, some have provided evidence of its inferiority. Strong consideration should be given to the use of alternative agents in the treatment of serious S. aureus infections.
Available from: Anurag Payasi
- "We found that 4.6% MRSA were resistant to Vancoplus while 26 to 80 % resistance observed for other drugs. The susceptibility of MRSA to vancomycin may be declining and reports of treatment failures are increasing     . The varied level of vancomycin resistance was reported from different parts of the world    . "
Available from: Vance G Fowler
- "Vancomycin, the most commonly used antibiotic in hospitalized patients with MRSA bacteremia, has several limitations , including the rise of strains with decreased susceptibility [6,7] or resistance [8,9] and suboptimal results for the treatment of patients with bacteremia due to methicillin-susceptible S. aureus (MSSA) [10,11]. Despite the dramatic consequences of SAB and the limitations of vancomycin, only one registrational, open-label, randomized clinical trial in patients with SAB has been conducted , and vancomycin remains first-line therapy for MRSA bacteremia in most settings . "
[Show abstract] [Hide abstract]
Staphylococcus aureus bacteremia is a common infection associated with significant morbidity and mortality. Telavancin is a bactericidal lipoglycopeptide active against Gram-positive pathogens, including methicillin-resistant S. aureus (MRSA). We conducted a randomized, double-blind, Phase 2 trial in patients with uncomplicated S. aureus bacteremia.
Patients were randomized to either telavancin or standard therapy (vancomycin or anti-staphylococcal penicillin) for 14 days. Continuation criteria were set to avoid complicated S. aureus bacteremia. The primary end point was clinical cure at 84 days.
In total, 60 patients were randomized and 58 received ≥1 study medication dose (all-treated), 31 patients fulfilled inclusion/exclusion and continuation criteria (all-treated target [ATT]) (telavancin 15, standard therapy 16), and 17 patients were clinically evaluable (CE) (telavancin 8, standard therapy 9). Mean age (ATT) was 60 years. Intravenous catheters were the most common source of S. aureus bacteremia and ~50% of patients had MRSA. A similar proportion of CE patients were cured in the telavancin (88%) and standard therapy (89%) groups. All patients with MRSA bacteremia were cured and one patient with MSSA bacteremia failed study treatment in each group. Although adverse events (AEs) were more common in the telavancin ATT group (90% vs. 72%), AEs leading to drug discontinuation were similar (7%) in both treatment arms. Potentially clinically significant increases in serum creatinine (≥1.5 mg/dl and at least 50% greater than baseline) were more common in the telavancin group (20% vs. 7%).
This study suggests that telavancin may have utility for treatment of uncomplicated S. aureus bacteremia; additional studies are warranted. (Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia (ASSURE); NCT00062647).
BMC Infectious Diseases 05/2014; 14(1):289. DOI:10.1186/1471-2334-14-289 · 2.61 Impact Factor
Available from: Paola Di Carlo
- "In our patient's case, the S. aureus isolate showed a vancomycin MIC of 2 mg/mL which was considered to be perhaps less effective against serious methicillin resistance, or a " bridge too far " in that the doses required carried a significant risk of toxicity . Guidelines therefore recommend therapy with alternative antimicrobials . "
[Show abstract] [Hide abstract]
ABSTRACT: Large cardiac vegetation carries a poor prognosis and high mortality risk, especially if associated with methicillin-resistant Staphylococcus aureus (MRSA) infection. We share our experience of a rare and complicated large cardiac vegetation which had a favourable outcome with combination antibiotic treatment alone. A 35-year-old HIV-negative, HCV-positive male patient with a previous history of methicillin-susceptible S. aureus endocarditis showed MRSA mitral valve endocarditis with large vegetation, complicated by embolic stroke. The strain was soon identified by PCR but only after culture did the patient receive efficacious antibiotics. A combination of daptomycin plus trimethoprim/sulfamethoxazole (TMP/SMX) was administered for six weeks, followed by a high dosage of TMP/SMX for a further six weeks. Effectiveness of the treatment was demonstrated by the patient's clinical improvement and instrumental evidence of cardiac mitral vegetation clearance. Innovative antibiotic strategies in patient management are needed to fight Staphylococcus aureus endocarditis because strains show varying antimicrobial susceptibility patterns in different geographic areas. Timely initiation of targeted antimicrobial therapy remains a crucial step to reduce morbidity and mortality but culture is crucial for appropriate fine-tuning of antibiotic therapy.
Le infezioni in medicina: rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 03/2013; 21(1):41-5.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.